Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark Rasak ... the Diamond Lifetime Achievement Award in the field of ... of Cardiovascular Clinical Associates. Dr. Rasak has ... all major aspects of the business; overseeing the daily ... primary coronary intervention. In addition, he is an honored ...
(Date:8/22/2014)... Ohio , Aug. 22, 2014 MC Medical, ... Inc. (MID), a Columbus, OH medical ... distribute the FloShield laparoscopic and robotic visualization system in ... be approved for sale in Japan ... a long-time experience and an extensive product portfolio in endoscopic ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2
... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
... Invasive Surgery at St.,Luke,s-Roosevelt Hospital Center completes his ... benefiting from ,hidden scar, procedure, CUPERTINO, Calif., ... completion of a series of single port Lap-Band,procedures ... pain for,patients. Dr. Julio Teixeira at St. Luke,s-Roosevelt ...
Cached Medicine Technology:Clinical Lab Products Magazine Features Biomoda 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 3
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... Eagerly embracing intended parents around the globe, ... offers the top male infertility programs — run by ... network of IVFinMexico.com continues to shape modern ... female and male infertility, advanced research and education. , ... eminently set by company CEO and Founder Tolga Umar ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
Breaking Medicine News(10 mins):Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... birth but develop accelerated head growth between six and ... onset of many behaviors that enable physicians to diagnose ... University of Washingtons Autism Center., The study also indicates ... have the early onset form of autism as well ...
... Store,s Gift of Mobility Fulfills Dreams of Terminally Ill,Stage Performer, ... his life in the public eye - whether he was ... or appearing in,television commercials. But two years ago, cancer robbed ... past year. To fulfill his,dream to get outside again, The ...
... BOCA RATON, Fla., Jan. 30 Spirit of ... bidding for the Spirit of Women,Celebrity Red Shoe ... will benefit several health,organizations, including the National Stroke ... for auction February 5,through February 14 were autographed ...
... Web address on all TV ads to report adverse,reactions, ... ads that sell the "good news" about prescription drugs,but ... on a petition to the FDA demanding the agency ... medications., The citizens, petition requests the Food and ...
... LANSING, Jan. 30 A report issued today ... policy consultancy,based in Washington, D.C., confirms that Blue ... million to the people of Michigan in 2007 ... to improve access to,health coverage at affordable prices. ...
... known to doctors as a hormone that boosts red-blood-cell production. ... PhD, an ophthalmologist at Children,s Hospital Boston, shows it also ... The findings not only add a new function to the ... prescribing it to patients with diseases affected by abnormal blood-vessel ...
Cached Medicine News:Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store 2Health News:Celebrities Encourage Women to Take Steps for Heart Health Through Online Red Shoe Charity Auction 2Health News:Petition Asks FDA to Make it Easier for Patients to Report Side Effects from Prescription Drugs 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3